The next step in psychedelic research may involve understanding the soundtrack as carefully as the substance. A new study of music during psilocybin examines how contrasting compositions influence emotion, bringing an often overlooked element of psychedelic settings into experimental focus.
The question extends beyond whether music sounds better. For researchers and clinicians, it concerns whether particular sounds guide different emotional experiences and whether those differences eventually matter for treatment.
An Established Practice With Unanswered Questions
Music is an established component of many psilocybin research protocols, but its therapeutic contribution remains difficult to isolate from the drug, psychological support, and broader setting.
A peer-reviewed study by Kaelen and colleagues examined interviews with 19 patients receiving psilocybin for treatment-resistant depression. Participants described music as a source of emotional expression, imagery, guidance, and safety. Some also reported unpleasant emotions or feeling directed toward experiences they resisted.
The quality of their music experience was associated with depression improvement one week later, while general drug intensity was not. However, this association could not establish that music caused improvement or identify an optimal playlist.
Testing Music During Psilocybin Under Controlled Conditions
Dojčánová and colleagues used an exploratory, double-blind, placebo-controlled crossover design in healthy adults. Participants received oral psilocybin at 0.26 mg/kg or placebo in separate sessions.
An initial group of 19 rated eight compositions. Researchers then selected one classical piece and one psytrance track for detailed emotional assessment in another 17 participants using the Geneva Emotional Music Scale.
During the drug’s plateau phase, psilocybin increased wonder, transcendence, and joyful activation across both compositions. Classical music elicited more peacefulness, tenderness, and nostalgia, while psytrance elicited more tension across both drug and placebo conditions.
Sadness showed a different pattern: psilocybin increased sadness during the classical composition and reduced it during psytrance. The September 2026 report is a preprint and has not undergone peer review.
Different Emotions Require Different Interpretations
These findings suggest an important distinction: a drug effect and a musical effect can coexist without music uniformly amplifying everything the drug produces.
Wonder and joyful activation should not be treated as interchangeable with peacefulness. Similarly, sadness does not automatically indicate an unsuccessful experience. An emotional rating describes what someone felt at a particular moment, rather than whether that experience produced lasting benefit.
For clinical interpretation, the essential question is what follows the emotion. Does it support useful reflection, become overwhelming, or have little consequence after the session? Answering that requires follow-up measures beyond immediate listening responses.
From Receptor Activity To Personal Meaning
The study’s pharmacological framework centers on psilocybin’s action at serotonin 5-HT2A receptors. Connecting that action to a specific emotional response to music requires additional evidence.
A plausible interpretation is that altered perception and emotional processing change how a listener experiences sound. Music then supplies structure, movement, and emotional cues that the individual interprets within that altered state.
This remains a hypothesis rather than a demonstrated mechanism. The reported emotional differences cannot establish which brain circuits produced them or whether those circuits mediate therapeutic change.
A Composition Comparison Is Not A Genre Verdict
The experimental approach helps move the discussion beyond retrospective impressions. Nevertheless, comparing two selected pieces cannot determine whether classical music or psytrance is generally preferable.
A useful next experiment would test multiple compositions within each genre, account for familiarity and preference, and include a silence condition. Otherwise, characteristics of one recording may be mistaken for properties of an entire musical category.
Toward More Informative Treatment Protocols
For the field, the immediate implication is a research priority: document music selection and timing alongside dose and psychological support. Trials should also distinguish emotional intensity, tolerability, personal meaning, and symptom improvement.
The eventual goal is a more responsive approach to session design. Before playlists can be prescribed for particular therapeutic outcomes, larger clinical studies must establish whether musical choices change recovery, rather than only the emotional tone of a session.
Citations
- Dojčánová D, et al. (2026). Psilocybin And Contrasting Musical Compositions: Effects On Music-Evoked Emotional Responses In Healthy Adults. medRxiv. Preprint.
- Kaelen M, et al. (2018). The Hidden Therapist: Evidence For A Central Role Of Music In Psychedelic Therapy. Psychopharmacology, 235, 505–519.
Explore more at https://www.interventionalpsychiatry.org/
